Atlas Trials

Recurrent Chronic Myelomonocytic Leukemia

17 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Chronic Myelomonocytic Leukemia

RecordFirmDate
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990)M.D. Anderson Cancer Center2021-07-07
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT04752163)M.D. Anderson Cancer Center2021-03-25
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631)Fred Hutchinson Cancer Center2020-12-03
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04550442)M.D. Anderson Cancer Center2020-09-04
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (NCT04239157)M.D. Anderson Cancer Center2020-08-25
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome (NCT04487106)M.D. Anderson Cancer Center2020-07-21
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (NCT04493138)M.D. Anderson Cancer Center2020-07-21
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant (NCT03807063)Fred Hutchinson Cancer Center2020-01-02
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT04140487)M.D. Anderson Cancer Center2019-12-17
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT03896269)M.D. Anderson Cancer Center2019-05-14
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (NCT02530034)M.D. Anderson Cancer Center2019-01-31
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)Fred Hutchinson Cancer Center2018-02-23
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193)M.D. Anderson Cancer Center2018-01-18
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01892371)M.D. Anderson Cancer Center2013-11-12

Track Recurrent Chronic Myelomonocytic Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.